Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rigel Optimistic On Fostamatinib Despite Narrow Phase III Benefit

Executive Summary

Rigel's SYK inhibitor fostamatinib met the primary endpoint in the first of two pivotal Phase III trials in chronic ITP, but yielded a treatment effect in only 18% of the patients. CEO Raul Rodriguez discussed the data in an interview.

You may also be interested in...



Keeping Track: A Fresh Wave Of Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Rigel Readies Tavalisse For Late-May Launch After FDA Approval

Rigel has its first US FDA approval for Tavalisse (fostamatinib) and plans to launch the drug for adults with immune thrombocytopenia (ITP) in late May, after working on the drug's development for more than a decade across multiple indications.

Rigel Mulls Next Steps After Fostamatinib Fails In Kidney Disease

Rigel sees positive signs for Tavalisse in failed mid-stage study in autoimmune nephropathy, but investors don't share the optimism, sending the stock down almost 14% on the news.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel